Development of a universal HIV-1 vaccine

A single injection could train the immune system to recognise and attack the parts of HIV that the virus cannot afford to change. HIV’s extraordinary ability to mutate has made it nearly impossible to design a vaccine that works against all circulating strains. The virus’s surface proteins shift constantly, allowing it to evade antibodies. But some regions of those proteins must stay stable for the virus to survive. This candidate vaccine deliberately targets those conserved regions, forcing the immune system to focus on the virus’s weak points rather than chasing its ever-changing disguise. If this small pilot study in healthy volunteers in Oxford shows that the approach is safe and provokes the right immune response, it would justify moving to larger, more expensive trials. A successful universal HIV vaccine would transform the fight against a pandemic that continues to spread largely unchecked. It would not cure people already infected, but it could prevent new infections on a global scale, reducing the need for lifelong antiretroviral therapy and shifting the trajectory of the epidemic. For now, the work remains at an early, fundamental stage—testing a concept that has never been tried in humans.